Generex awarded two Japanese, one U.S. patent for Oral-lyn oral insulin product

By Lisa Kerner

Charlotte, N.C., July 28 - Generex Biotechnology Corp. was awarded its first Japanese patents and a new U.S. patent for its oral insulin product, Oral-lyn.

The two Japanese patents contain claims relating to an improved delivery system for the administration of large-molecule pharmaceuticals by means of an aerosol into the mouth, for buccal or pulmonary application, according to a company news release.

Generex' U.S. patent contains claims related to an improved delivery system for the administration of large-molecule pharmaceuticals through the oral and nasal membranes.

The company now holds 76 patents worldwide, with 19 of those in the United States, and 51 patent applications pending.

Toronto-based Generex develops drug delivery systems and technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.